Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Platinum Pharmaceuticals

Private pharmaceutical manufacturer · Karachi · Pakistan

Karachi-based pharmaceutical manufacturer serving domestic and export markets from the Bin Qasim industrial zone.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation22 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date4 Aug 2026Newest effective date among published current price records
Corporate profile evidence4 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
Platinum Pharmaceuticals (Pvt.) Ltd.
Company type
Private pharmaceutical manufacturer
Address
A-20, North Western Industrial Zone, Bin Qasim, Karachi 75020, Pakistan · 75020
Phone
+92 21 34750112-3
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
88%
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000415 161 linked products · source seen 22 Sep 2026 View source ↗
Corporate profile source ledger Contact Page Url source ↗ Logo Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx162public portfolio records represented
REG108unique registrations represented
IDX161indexed MedInfoBase presentations
SRC1additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR152current validated price records
G56generic molecules in indexed catalogue
DF9dosage-form groups
TA10therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage94%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage98%
priced packs safely normalized per unit
Comparable-market coverage89%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixPlatinum PharmaceuticalsShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/platinum-pharmaceuticalsGenerated 23 Sep 2026CNS & mental health55 · 34%Anti-infectives45 · 28%Respiratory & allergy19 · 12%Cardiovascular17 · 11%Oncology & immunology6 · 4%Vitamins, minerals & nutrition5 · 3%Reproductive & genitourinary5 · 3%Other therapeutic areas9 · 6%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioPlatinum PharmaceuticalsDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/platinum-pharmaceuticalsGenerated 23 Sep 2026161presentationsTablet99 · 61%Capsule17 · 11%Suspension15 · 9%Syrup9 · 6%Inhalation8 · 5%Solution7 · 4%Other forms6 · 4%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionPlatinum PharmaceuticalsCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/platinum-pharmaceuticalsGenerated 23 Sep 2026144comparable productsBelow peer median9 · 6%Near peer median38 · 26%Above peer median97 · 67%Company median price position+10.2%Lowest-price equivalents9Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsPlatinum PharmaceuticalsCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/platinum-pharmaceuticalsGenerated 23 Sep 2026Nabiqasim Industries (Pvt) Ltd.,34 shared61% overlapCCL Pharmaceuticals (Pvt.) Limited30 shared54% overlapMediate Pharmaceutical Pvt Ltd30 shared54% overlapGenome Pharmaceuticals (Pvt.) Ltd.30 shared54% overlapBio-Labs(Pvt) Ltd29 shared52% overlapWerrick Pharmaceuticals28 shared50% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

CNS & mental health55 products · 34%
Anti-infectives45 products · 28%
Respiratory & allergy19 products · 12%
Cardiovascular17 products · 11%
Oncology & immunology6 products · 4%
Vitamins, minerals & nutrition5 products · 3%
Reproductive & genitourinary5 products · 3%
Hematology & thrombosis4 products · 2%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antiepileptics31 products · 19%
Antipsychotics12 products · 7%
Antimalarials12 products · 7%
Antihistamines11 products · 7%
Macrolide antibacterials10 products · 6%
Beta blockers8 products · 5%
SSRI antidepressants8 products · 5%
Immunosuppressants / immunomodulators6 products · 4%
Formulation footprint

Dosage forms

Tablet99 products
Capsule17 products
Suspension15 products
Syrup9 products
Inhalation8 products
Solution7 products
Cream2 products
Pessary2 products
Sachet2 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 LEVOTAMLevetiracetam 11presentations 1 g, 100 MG/mL, 100 mg/mL, 250 mg · Tablet, Solution #2 SEIZUNILCarbamazepine 9presentations 100 mg/5 mL, 200 mg, 400 MG, 400 mg · Suspension, Tablet #3 FEXOFASTFexofenadine 7presentations 120 mg, 180 mg, 30 mg/5 mL, 30 MG/5 mL · Tablet, Solution #4 PLAZOAzithromycin 7presentations 200 mg/5 mL, 250 MG, 500 mg, 500 MG · Suspension, Tablet #5 ARIPAAripiprazole 6presentations 10 mg, 15 mg · Tablet #6 CARDAXENAtenolol 5presentations 100 mg, 25 mg, 50 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median96% of comparable products
Near market median38within ±5% of median
Above market median9767% of comparable products
Lowest-price equivalents9ties included
Company median price position +10.2% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Empanum 10 mgEmpagliflozin · Tablet · 2x7's PKR 46.43/tablet-43.8% vs market median BLICOR 10 mgBisoprolol fumarate · Tablet · 2x10's PKR 14.85/tablet-32.9% vs market median CITALO 20 mgCitalopram · Tablet · 10'S PKR 41.07/tablet-29.1% vs market median BlicorTablet 2.5 mgBisoprolol fumarate · Tablet · 14's PKR 3.22/tablet-24.5% vs market median BlicorTablet 2.5 mgBisoprolol fumarate · Tablet · 10's PKR 3.32/tablet-22.1% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 34shared generics CCL Pharmaceuticals (Pvt.) Limited249 products · 99 generics 30shared generics Mediate Pharmaceutical Pvt Ltd236 products · 90 generics 30shared generics Genome Pharmaceuticals (Pvt.) Ltd.181 products · 84 generics 30shared generics Bio-Labs(Pvt) Ltd236 products · 82 generics 29shared generics Werrick Pharmaceuticals249 products · 82 generics 28shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers107Distinct registrations among indexed, published, presentation-validated products only
Verified price observations167
Products with a verified price161
Products with multiple price observations6
Source records with multiple versions161
Latest portfolio source check22 Sep 2026
Latest effective price date4 Aug 2026
Latest source observation22 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

108 unique registration(s) · 161 indexed presentation(s) · 1 additional source-observed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
APOFER Iron polymaltose complex 100 mg Tablet 10'S 023887 PKR 194.59 PKR 19.46/tablet 37% above median
APOFER Iron 50 MG/5 mL Syrup 60ml 030204 PKR 194.59 PKR 3.24/mL 35% above median
APOFER Iron 50 MG/5 mL Syrup 120ml 030204 PKR 367.58 PKR 3.06/mL 27% above median
APOFER-F Iron polymaltose complex + Folic acid 100 mg elemental iron + 0.75 mg folic acid Tablet 10'S 023888 PKR 194.59 PKR 19.46/tablet No comparator
APOFER-F Iron polymaltose complex + Folic acid 100 mg + 0.75 mg Tablet 30's 023888 PKR 509.02 PKR 16.97/tablet No comparator
ARBIMOX Moxifloxacin 400 MG Tablet 5'S 048588 PKR 994.59 PKR 198.92/tablet 8% above median
ARIPA Aripiprazole 10 mg Tablet 30'S 055708 PKR 462.07 PKR 15.40/tablet Near median
ARIPA Aripiprazole 10 mg Tablet 10'S 055708 PKR 192.54 PKR 19.25/tablet 25% above median
ARIPA Aripiprazole 10 mg Tablet 20'S 055708 PKR 308.05 PKR 15.40/tablet Near median
ARIPA Aripiprazole 15 mg Tablet 30'S 055709 PKR 683.46 PKR 22.78/tablet Near median
ARIPA Aripiprazole 15 mg Tablet 10'S 055709 PKR 284.78 PKR 28.48/tablet 25% above median
ARIPA Aripiprazole 15 mg Tablet 20'S 055709 PKR 455.64 PKR 22.78/tablet Near median
ARTEQUINE Dihydroartemisinin + Piperaquine 40 mg + 320 mg Capsule 8'S 055908 PKR 821.62 PKR 102.70/capsule 8% above median
ARTEQUINE Dihydroartemisinin + Piperaquine 15 mg + 120 mg Sachet 16'S 058556 PKR 759.11 PKR 47.44/sachet 5% below median
ARTEQUINE Dihydroartemisinin + Piperaquine 15 mg + 120 mg/sachet Sachet 8'S 058556 PKR 379.55 PKR 47.44/sachet No comparator
ARTEQUINE Dihydroartemisinin + Piperaquine 40 mg + 320 mg Tablet 8'S 061468 PKR 698.39 PKR 87.30/tablet Near median
ARTEQUINE DRY Dihydroartemisinin + Piperaquine 15 mg + 120 mg/5 mL Dry suspension 80ML 061467 PKR 607.29 PKR 7.59/mL No comparator
ARTEQUINE DRY DIHYDROARTEMISININ 15 mg/5 mL Dry suspension 30ML 061467 PKR 239.71 PKR 7.99/mL 5% above median
ARTEQUINE DRY DIHYDROARTEMISININ 15 mg/5 mL Dry suspension 60ML 061467 PKR 455.47 PKR 7.59/mL Near median
AVEC Cetirizine 10 mg Tablet 20's 025506 PKR 184.97 PKR 9.25/tablet 16% above median
AVEC Cetirizine 10 mg Tablet 10'S 025506 PKR 94.38 PKR 9.44/tablet 18% above median
AVEC Cetirizine 5 mg/5 mL Syrup 60ml 025507 PKR 91.33 PKR 1.52/mL 46% above median
AVEC Cetirizine 5 mg/5 mL Syrup 120ML 025507 PKR 179.00 PKR 1.49/mL 44% above median
BLICORSource observed Bisoprolol as Fumarate ……… 5 mg Tablet 20's 105358Official source ↗ No indexed price — —
BLICOR Bisoprolol fumarate 10 mg Tablet 2x10's 114336 PKR 297.06 PKR 14.85/tablet 33% below median
BlicorTablet Bisoprolol fumarate 2.5 mg Tablet 10's 105357 PKR 33.19 PKR 3.32/tablet 22% below median
BlicorTablet Bisoprolol fumarate 2.5 mg Tablet 14's 105357 PKR 45.02 PKR 3.22/tablet 25% below median
BOKAY Paroxetine 20 mg Tablet 10'S 035606 PKR 698.24 PKR 69.82/tablet Near median
CABOK Amlodipine 5 mg Tablet 3x10's 020170 PKR 413.24 PKR 13.77/tablet 27% above median
CABOK Amlodipine 5 mg Tablet 20's 020170 PKR 275.50 PKR 13.78/tablet 27% above median
CABOK Amlodipine 10 mg Tablet 3x10's 020171 PKR 825.22 PKR 27.51/tablet 62% above median
CABOK Amlodipine 10 mg Tablet 20'S 020171 PKR 550.15 PKR 27.51/tablet 62% above median
CARDAXEN Atenolol 50 mg Tablet 20'S 020173 PKR 178.28 PKR 8.91/tablet 24% above median
CARDAXEN Atenolol 50 mg Tablet 14'S 020173 PKR 163.14 PKR 11.65/tablet 62% above median
CARDAXEN Atenolol 100 mg Tablet 20'S 020174 PKR 277.65 PKR 13.88/tablet 35% above median
CARDAXEN Atenolol 100 mg Tablet 14's 020174 PKR 249.02 PKR 17.79/tablet 73% above median
CARDAXEN Atenolol 25 mg Tablet 20'S 024461 PKR 112.46 PKR 5.62/tablet 14% above median
CEFTAS Cefixime 400 MG Capsule 5'S 026166 PKR 592.03 PKR 118.41/capsule Near median
CEFTAS Cefixime 200 mg/5 mL Suspension 30ml 045018 PKR 404.31 PKR 13.48/mL Near median
CEFTAS Cefixime 200 mg/5 mL Suspension 100ml 045018 PKR 1,293.79 PKR 12.94/mL Near median
CEFTAS Cefixime 200 MG Capsule 5'S 045213 PKR 351.90 PKR 70.38/capsule 12% above median
CEFTAS DRY Cefixime 100 mg/5 mL Dry suspension 30ml 026165 PKR 330.39 PKR 11.01/mL 5% above median
CITALO Citalopram 20 mg Tablet 10'S 028126 PKR 410.74 PKR 41.07/tablet 29% below median
CLOPIDO Clopidogrel 75 mg Tablet 3x10's 035608 PKR 844.23 PKR 28.14/tablet Near median
CLOPIDO Clopidogrel 75 mg Tablet 10'S 035608 PKR 293.14 PKR 29.31/tablet 8% above median
CLOPIDO PLUS 150 Clopidogrel + Aspirin 75 mg + 150 mg Tablet 10'S 055741 PKR 299.65 PKR 29.97/tablet Near median
CLOPIDO PLUS 75 Clopidogrel + Aspirin 75 mg + 75 mg Tablet 10'S 055740 PKR 286.38 PKR 28.64/tablet Near median
CURAGEST PESSARIES Progesterone 200 mg Pessary 15'S 048423 PKR 2,162.20 PKR 144.15/pessary No comparator
CURAGEST PESSARIES Progesterone 400 mg Pessary 15'S 048424 PKR 3,243.29 PKR 216.22/pessary No comparator
DAPAKAN Divalproex sodium 250 mg Tablet 30'S 024464 PKR 254.32 PKR 8.48/tablet 14% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Platinum Pharmaceuticals — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/platinum-pharmaceuticals/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.